tradingkey.logo

Design Therapeutics Inc <DSGN.OQ> expected to post a loss of 33 cents a share - Earnings Preview

ReutersAug 1, 2025 2:53 PM
  • Design Therapeutics Inc DSGN.OQ DSGN.O is expected to show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Design Therapeutics Inc is for a loss of 33 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Design Therapeutics Inc is $5.00, about 22.6% above its last closing price of $3.87

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.29

-0.28

-0.31

Missed

-10.7

Dec. 31 2025

-0.27

-0.24

Beat

10

Sep. 30 2024

-0.22

-0.24

-0.23

Beat

5.5​

Jun. 30 2024

-0.21

-0.23

-0.21

Beat

10

​​Mar. 31 2024

-0.25

-0.26

-0.20

Beat

24.1

Dec. 31 2023

-0.31

-0.21

Beat

32.2​

Sep. 30 2023

-0.38

-0.41

-0.28

Beat

31.5

Jun. 30 2023

-0.39

-0.40

-0.36

Beat

9.4

This summary was machine generated August 1 at 14:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI